Affordable Access

deepdyve-link
Publisher Website

Role of early detection and pharmacotherapy in chronic obstructive pulmonary disease.

Authors
  • Diaz, Philip1
  • Bruns, Aaron
  • Rittinger, Mahasti
  • Kadiev, Steven
  • 1 COPD Treatment Program, 201 Davis Heart Lung Research Institute, 473 West 12th Avenue, The Ohio State University, Columbus, OH 43210, USA. [email protected]
Type
Published Article
Journal
Expert Review of Respiratory Medicine
Publisher
Informa UK (Taylor & Francis)
Publication Date
Dec 01, 2008
Volume
2
Issue
6
Pages
779–789
Identifiers
DOI: 10.1586/17476348.2.6.779
PMID: 20477239
Source
Medline
License
Unknown

Abstract

Chronic obstructive pulmonary disease (COPD) is defined as airflow limitation that is not fully reversible, usually progressive and associated with an abnormal inflammatory response to noxious particles or gases. By the time COPD has progressed to the point of clinical symptoms, over half of lung function may have been lost. This review will first describe studies that have examined the feasibility and yield of early detection of COPD using spirometry as a gold standard. Next, we will review existing studies that have examined the effects of pharmacotherapy on early (mild-to-moderate) COPD, specifically focusing on studies that have attempted to alter the natural history of disease. Finally, we will briefly discuss studies that have tested the effects of various pharmacologic interventions on biomarkers felt to be relevant to disease pathogenesis. Discovery of effective pharmacotherapy that can prevent disease progression in early-stage COPD has enormous public-health implications, given the current global burden of disease and the proportion of individuals at risk - aging current and former smokers.

Report this publication

Statistics

Seen <100 times